729

Phospho-Tuberin/TSC2 (Ser664) (D3B9Z) Rabbit mAb



Orders:	877-616-CELL (2355 orders@cellsignal.com			
Support:	877-678-TECH (8324			
Web:	info@cellsignal.com cellsignal.com			

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 200	Source/Isotype: Rabbit IgG	UniProt ID: #P49815	Entrez-Gene Id: 7249		
Product Usage Information		ApplicationDilutionWestern Blotting1:1000Immunoprecipitation1:50						
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.						
Specificity/Sensitivity		Phospho-Tuberin/TSC2 (Ser664) (D3B9Z) Rabbit mAb recognizes endogenous levels of Tuberin/TSC2 protein only when phosphorylated at Ser664. This antibody cross-reacts with a 140kD protein of unknown origin.						
Source / Purific	cation	Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser664 of human Tuberin/TSC2 protein.						
Background		Tuberin is a product of the TSC2 tumor suppressor gene and an important regulator of cell proliferation and tumor development (1). Mutations in either <i>TSC2</i> or the related <i>TSC1</i> (hamartin) gene cause tuberous sclerosis complex (TSC), an autosomal dominant disorder characterized by development of multiple, widespread non-malignant tumors (2). Tuberin is directly phosphorylated at Thr1462 by Akt/PKB (3). Phosphorylation at Thr1462 and Tyr1571 regulates tuberin-hamartin complexes and tuberin activity (3-5). In addition, tuberin inhibits the mammalian target of rapamycin (mTOR), which promotes inhibition of p70 S6 kinase, activation of eukaryotic initiation factor 4E binding protein 1 (4E-BP1, an inhibitor of translation initiation), and eventual inhibition of translation (3,6,7). p44/42 MAPK (Erk1/2) phosphorylates of TSC2 at Ser664 which leads to TSC1-TSC2 dissociation and considerably decreases the ability of TSC2 to inhibit mTOR signaling, cell proliferation and oncogenic transformation (8,9). Furthermore, studies have indicated that cancer patients with TSC2 phosphorylation at Ser664 may benefit from MAPK and mTOR inhibitors (10).						
Background References		1. Soucek, T. et al. (1994 2. Sparagana, S.P. and I 3. Manning, B.D. et al. (4. Aicher, L.D. et al. (2002 5. Dan, H.C. et al. (2002 6. Goncharova, E.A. et a 7. Inoki, K. et al. (2002) 8. Ma, L. et al. (2005) <i>C</i> 9. Ballif, B.A. et al. (2007) <i>C</i>	8) Proc Natl Acad S Roach, E.S. (2000) (2002) Mol Cell 10, 01) J Biol Chem 276) J Biol Chem 277, 3 al. (2002) J Biol Che Nat Cell Biol 4, 648 ell 121, 179-93. 5) Proc Natl Acad S Cancer Res 67, 710	<i>ci U S A</i> 95, 15653-8. <i>Curr Opin Neurol</i> 13, 115 151-62. , 21017-21. 35364-70. <i>m</i> 277, 30958-67. 3-57. <i>ci U S A</i> 102, 667-72. 6-12.	ı-9.			
Species Reactiv	vitv	Species reactivity is det	ermined by testing	n in at least one approve	d application (e.g.,	western blot).		
Western Blot B	Slot Buffer IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.					n 5% w/v BSA, 1X		
Applications K	ey	W: Western Blotting IP	: Immunoprecipita	tion				
Cross-Reactivit	ty Key	H: Human						
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.						
		All other trademarks ar more information.	re the property of t	heir respective owners.	Visit cellsignal.com	/trademarks for		

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.